Leadership

Dr. Angulo became President and Chief Executive Officer of SCYNEXIS, as well as a member of the Board of Directors, in January 2023. Dr. Angulo joined SCYNEXIS in 2015 as Chief Medical Officer. An infectious disease specialist with more than 20 years of experience in successful drug development, he previously served as Vice President, Research and Development of Brickell Biotech, Inc.

Prior to joining Brickell, Dr. Angulo held various senior positions at Stiefel Laboratories, Inc., a GSK company, including head of the clinical and medical departments. Dr. Angulo was also responsible for several development programs in the anti-infectives area at Schering-Plough Research Institute and was an infectious disease physician in a pediatric hospital. He received his medical degree from the Universidad de Guadalajara, Mexico, and has post-graduate degrees in pediatrics and infectious diseases.

Mr. Sukenick joined SCYNEXIS as General Counsel in November 2017 after over a decade of addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development.

Mr. Sukenick most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management. Prior to that, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career at Simpson Thacher & Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.

Sanjay Subramanian joined SCYNEXIS as Chief Financial Officer in September 2026. He is an accomplished biopharmaceutical finance executive with more than 20 years of experience in finance, capital markets, business development, and corporate strategy. Prior to joining SCYNEXIS, Mr. Subramanian served as Chief Financial Officer and Head of Business Development at Inozyme Pharma, where he led finance, investor relations, legal, and business development activities and played a key role in the company’s acquisition by BioMarin Pharmaceutical. Previously, he served as Chief Financial Officer and Head of Corporate Development at Ocugen, Inc. Earlier in his career, he held finance leadership positions at Aralez Pharmaceuticals, Bausch Health Companies, and General Motors. Mr. Subramanian earned an M.B.A. from the MIT Sloan School of Management, a Master of Science from the Massachusetts Institute of Technology, a Master of Science from The Ohio State University, and a Bachelor of Science from the Indian Institute of Technology (IIT) Madras.

Daniella Gigante joined SCYNEXIS to lead the Human Resources and IT functions in October 2020. She has over 22 years of Human Resources experience in various industries including Consulting, Banking, Pharmaceutical and Bio-technology. Prior to SCYNEXIS, Ms. Gigante spent 8 years at Allergan where she was the Executive Director of Talent Acquisition. Previously she worked at Pfizer and Schering-Plough responsible for leading Talent Acquisition teams. Prior to that she led an HR Reporting and Analytics team at Washington Mutual Bank. Ms. Gigante holds a Master of Arts in Industrial and Organizational Psychology from the Fairleigh Dickinson University and a Bachelor of Arts in Psychology from the Hofstra University.

Rossana Ferrara-Pontoriero joined SCYNEXIS in September 2016 and has held various leadership roles in Commercial, Business Development, Strategic Planning, and Alliance Management. Dr. Ferrara-Pontoriero is a Commercial and Business Development executive with over 11 years’ experience in the Pharmaceutical and Biotechnology industries. Prior to SCYNEXIS, she worked in Marketing roles at Celgene and Allergan as well as Global Commercial Assessments at Forest Laboratories. Dr. Ferrara-Pontoriero received her PhD in Medicinal Chemistry from Università degli Studi di Milano, her Master’s in Pharmacy from the Università degli Studi di Salerno, and her MBA in Pharmaceutical Management from Rutgers Business School.